慢性髓性白血病患者的临床谱及治疗反应与ABO血型的相关性

Clinical spectrum and treatment response in patient of chronic myeloid leukemia in correlation with ABO blood group.

作者信息

Meher Mukti P, Gupta Saumya, Singh Arun Kumar, Kumar Prabhat, Kumar Sandeep, Amrit Amar Kumar, Arora Disha, Bharti Anju, Kumar Sandip, Meena Lalit Prashant

机构信息

Department of General Medicine, Institute of Medical Sciences Banaras Hindu University, Varanasi, Uttar Pradesh, India.

Department of Pathology, Institute of Medical Sciences Banaras Hindu University, Varanasi, Uttar Pradesh, India.

出版信息

J Family Med Prim Care. 2022 Jul;11(7):3449-3454. doi: 10.4103/jfmpc.jfmpc_2167_21. Epub 2022 Jul 22.

DOI:10.4103/jfmpc.jfmpc_2167_21

PMID:36387650

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9648264/

Abstract

BACKGROUND

Several studies have been conducted to evaluate and investigate the molecular mechanisms underlying alterations in ABO blood group antigens in oncogenesis. We observed that no study has been reported yet that correlate cytological, molecular and haematological responses of Imatinib therapy in chronic myeloid leukemia (CML) patients with different types of blood groups.

OBJECTIVE

To determine the distribution of CML in the ABO blood group, clinical spectrum of CML in different blood groups, and treatment response of CML patients in correlation with ABO and Rh blood groups.

MATERIAL AND METHODS

All the patients included in the study were diagnosed on the basis of clinical features, peripheral smears and bone marrow aspiration findings. Real-time reverse transcriptase polymerase chain reaction (PCR) and cytogenetic analysis were done in all patients at the time of initiation of therapy. Blood grouping and Rh typing of each patient were done at the initiation of therapy.

RESULTS

Out of 100 included patients, 58 were male and 42 were female patients. It was observed that 45 (45%) patients were having a B+ blood group; 33% patients were having O+ blood group, followed by A+ (10%), AB+ (8%), A- (2%), B- (1%) and AB- (1%). Around 43.64% study subjects with O + blood groups showed complete cytogenetic response, followed by B+ (41.82%), A+ (10.91), A- (1.82) and AB+ (1.82). An equal number of patients (40% each) with O+ and B+ blood groups, followed by A+ (20%) showed undetectable Abelson-breakpoint cluster region (BCR-ABL)/ratio (%). About 75% of patients showed complete haematological response (CHR) and 25% showed PHR. Patients with B+ and O+ blood groups (41.33%) showed a CHR. It was observed that a maximum number of patients were suffering from symptoms of an abdominal mass (37%), 43.24% of patients with B+ blood group showed an abdominal mass, followed by O+ (35.13%), A+ and AB+ (8.11% each), B - and AB- (2.70% each).

CONCLUSION

This study revealed that study subjects with B+ and O+ blood groups showed better cytogenetic, molecular and haematological responses as compared with patients with other blood groups at 6 and 12 months of treatment with Imatinib.

摘要

背景

已经开展了多项研究来评估和探究肿瘤发生过程中ABO血型抗原改变的分子机制。我们观察到，尚未有研究报道慢性髓性白血病（CML）患者不同血型与伊马替尼治疗的细胞学、分子学及血液学反应之间的相关性。

目的

确定CML在ABO血型中的分布、不同血型CML的临床谱，以及CML患者与ABO和Rh血型相关的治疗反应。

材料与方法

纳入研究的所有患者均根据临床特征、外周血涂片及骨髓穿刺结果进行诊断。所有患者在开始治疗时均进行实时逆转录聚合酶链反应（PCR）和细胞遗传学分析。每位患者在开始治疗时进行血型鉴定和Rh分型。

结果

在纳入研究的100例患者中，男性58例，女性42例。观察到45例（45%）患者为B+血型；33%的患者为O+血型，其次是A+（10%）、AB+（8%）、A-（2%）、B-（1%）和AB-（1%）。约43.64%的O+血型研究对象显示完全细胞遗传学反应，其次是B+（41.82%）、A+（10.91%）、A-（1.82%）和AB+（1.82%）。O+和B+血型的患者中，有相等比例（均为40%）的患者检测不到Abelson断点簇区域（BCR-ABL）/比值（%），其次是A+（20%）。约75%的患者显示完全血液学反应（CHR），25%显示部分血液学反应（PHR）。B+和O+血型的患者（41.33%）显示CHR。观察到最多患者出现腹部肿块症状（37%），43.24%的B+血型患者出现腹部肿块，其次是O+（35.13%）、A+和AB+（均为8.11%）、B -和AB-（均为2.70%）。